Cancer name Breast Cancer
Cancer Type BRCA
Immunotherapy type Oncolytic viruses
Treatment WR.TK-Luc+
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature Tregs
Official Symbol Natural regulatory T (Treg) cell
Mode of action CE_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description We further examined what changes occurred in the tumor after viral therapy and saw that, for different tumor models(4T1, MC38, and Renca), the addition of vaccinia therapy resulted in a rapid loss of Treg, but that MDSC levels were unaffected (and actually continued to increase overtime, as they also did in control groups).
PMID 27374223
Title Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy